Trial Profile
A Dose Escalation of Zarnestra (R115777) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 May 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Tipifarnib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2008 New trial record.